Urocortin-2

Summary

Urocortin-2 (Ucn2) is an endogenous 38-amino acid neuropeptide belonging to the CRF superfamily, selective for the CRF2 receptor subtype. It plays roles in cardiovascular regulation (positive inotropy, vasodilation), stress response modulation, appetite suppression, and metabolic homeostasis. Preclinical and early clinical studies have explored its potential in heart failure, where it demonstrates hemodynamic benefits including reduced preload/afterload and improved cardiac output. It remains an investigational compound with no approved therapeutic indication.

Mechanism of Action

Selective agonist of corticotropin-releasing factor receptor type 2 (CRF2R/CRHR2), modulating cardiovascular function, stress response, energy homeostasis, and appetite regulation; activates adenylyl cyclase via Gs-protein coupling, increasing cAMP levels in target tissues including heart, skeletal muscle, and vasculature.

Routes of Administration

Goals & Uses

• Heart failure treatmentCardiovascularModerate
• Stress response modulationNeuropsychiatricLow
• Muscle preservation / anabolic effectsMusculoskeletalLow
• Vasodilation and afterload reductionCardiovascularModerate
• Appetite suppression / weight regulationMetabolicLow

Contraindications

• HypovolemiaCardiovascularHigh
• Obstructive cardiomyopathyCardiovascularModerate
• Hypersensitivity to Ucn2 or CRF-family peptidesAllergy/ImmunologyHigh
• Severe hypotensionCardiovascularHigh

Adverse Effects

• HeadacheNeurologicUncommonPain in the head or upper neck
• HypotensionCardiovascularCommonLow blood pressure
• FlushingVascularCommonWarmth and redness of the skin
• TachycardiaCardiovascularUncommonAbnormally fast heart rate
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit

Drug Interactions

• Antihypertensive agentsModerate
• CRF1R antagonistsLow
• Vasodilators (e.g., nitrates, hydralazine)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• Renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Elderly patientsAgeRelative

Regulatory Status

• European UnionInvestigationalNo EMA approval; limited investigational use in academic and clinical research settings.
• United StatesInvestigationalNo FDA approval; studied under IND applications in early-phase heart failure trials.
• United KingdomInvestigationalNo MHRA approval; research use only.

Not approved by any regulatory agency for therapeutic use. Studied in early-phase clinical trials primarily in heart failure patients. Synthetic analogs are under investigation.

Evidence & Sources

No sources recorded yet.